Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines proposed a classification for allergic rhinitis based on the duration of symptoms (intermittent, persistent) rather than on the time of allergen exposure (seasonal, perennial). There is no placebo‐controlled, randomized clinical trial on intermittent allergic rhinitis (IAR) to date. Desloratadine (DL) is recommended for the first‐line treatment of seasonal and perennial allergic rhinitis. Objectives: To assess the efficacy and safety of DL in subjects with IAR based on the ARIA classification. Methods: Patients over 12 years of age with IAR were assessed over 15 days of treatment with DL 5 mg once daily (n = 276) or placebo (n = 271). The primary endpoint was the AM/PM reflective total 5 symptom score (T5SS). Secondary endpoints included AM/PM instantaneous T5SS and individual symptoms, therapeutic response, symptom severity by visual analogue scale, and quality‐of‐life. Results: The mean reduction of AM/PM reflective T5SS was significantly greater with DL than with placebo over 15 days (−3.01 vs−2.13, P < 0.001) and on each individual day (P < 0.05). Mean AM instantaneous T5SS was reduced significantly with DL compared to placebo as early as day 2 (−1.84 vs−0.89; P < 0.001). The therapeutic response and improvement in quality‐of‐life were significantly greater with DL than with placebo (P < 0.001 for each). The frequency of treatment‐related adverse events was low and similar between DL (7.2%) and placebo (7.0%). Conclusions: This is the first large trial to show that treatment can be effective in IAR. Desloratadine was effective and safe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Self-citationAllergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
Self-citationQuality of Life in Allergic Rhinitis and Asthma
LEYNAERT, B., NEUKIRCH, C., LIARD, R., BOUSQUET, J., & NEUKIRCH, F. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.4.9912033 · Cited by 407
Self-citationSeverity and impairment of allergic rhinitis in patients consulting in primary care
Bousquet, J., Neukirch, F., Bousquet, P. J., Gehano, P., Klossek, J. M., Le Gal, M., & Allaf, B. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.09.047 · Cited by 298 · cited 4×
“It is also associated with significant impairments in social life (9–11) andwork (12, 13).”
BackgroundMethodResultSelf-citationLamb, C. E., Ratner, P. H., Johnson, C. E., Ambegaonkar, A. J., Joshi, A. V., Day, D., Sampson, N., & Eng, B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112552 · Cited by 288 · cited 1×
“3 h/workday when symptoms were present (37).”
Evaluation of Impermeable Covers for Bedding in Patients with Allergic Rhinitis
Terreehorst, I., Hak, E., Oosting, A. J., Tempels-Pavlica, Z., de Monchy, J. G. R., Bruijnzeel-Koomen, C. A. F. M., Aalberse, R. C., & Gerth van Wijk, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023171 · Cited by 224
Bachert, C., Bousquet, J., Canonica, G. W., Durham, S. R., Klimek, L., Mullol, J., Van Cauwenberge, P. B., & Van Hammée, G. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.05.070 · Cited by 215 · cited 6×
“Accepted for publication 24 April 2009 Abbreviations: ACCEPT-1, Aerius Control: Clinical and Evaluative Profile of Treatment-1; AM/PM, average of daily AM and PM evaluations; ARIA, Allergic Rhinitis and its Impact on Asthma; DL, desloratadine; GA2LEN, Global Allergy and Asthma European Network; IAR, intermittent aller…”
BackgroundMethodInfluentialSelf-citationCosts associated with persistent allergic rhinitis are reduced by levocetirizine
Bousquet, J., Demarteau, N., Mullol, J., van den Akker‐van Marle, M. E., Van Ganse, E., Bachert, C., & for the XPERT study group (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00820.x · Cited by 71
Self-citation
Cited by
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
Bousquet, J., Schünemann, H. J., Samolinski, B., Demoly, P., Baena-Cagnani, C. E., Bachert, C., Bonini, S., Boulet, L. P., Bousquet, P. J., Brozek, J. L., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.053 · Cited by 623
Self-citationKlimek, L., Bergmann, K.-C., Biedermann, T., Bousquet, J., Hellings, P., Jung, K., Merk, H., Olze, H., Schlenter, W., Stock, P., et al. (2017) · Allergo Journal International · doi:10.1007/s40629-016-0006-7 · Cited by 475
Self-citationImpact of Allergic Rhinitis Symptoms on Quality of Life in Primary Care
Bousquet, P. J., Demoly, P., Devillier, P., Mesbah, K., & Bousquet, J. (2013) · International Archives of Allergy and Immunology · doi:10.1159/000342991 · Cited by 204
Self-citationMACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
Bousquet, J., Schünemann, H. J., Hellings, P. W., Arnavielhe, S., Bachert, C., Bedbrook, A., Bergmann, K.-C., Bosnic-Anticevich, S., Brozek, J., Calderon, M., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.025 · Cited by 168
Self-citationHow representative are clinical study patients with allergic rhinitis in primary care?
Costa, D. J., Amouyal, M., Lambert, P., Ryan, D., Schünemann, H. J., Daures, J. P., Bousquet, J., & Bousquet, P. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.10.058 · Cited by 63
Self-citation
Metadata
- Authors
- Bousquet, J., Bachert, C., Canonica, G. W., Mullol, J., Van Cauwenberge, P., Bindslev Jensen, C., Fokkens, W. J., Ring, J., Keith, P., Lorber, R., Zuberbier, T., & The ACCEPT‐1 study group
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2009-09-15
- Volume
- 64
- Issue
- 10
- Pages
- 1516-1523
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2016486749
- Cited by
- 62
- References
- 8
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study. https://app.cochat.ai/papers/10.1111/j.1398-9995.2009.02115.x
- The paper
- Bousquet, J., Bachert, C., Canonica, G. W., Mullol, J., Van Cauwenberge, P., Bindslev Jensen, C., Fokkens, W. J., Ring, J., Keith, P., Lorber, R., Zuberbier, T., & The ACCEPT‐1 study group. (2009). Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study. Allergy. https://doi.org/10.1111/j.1398-9995.2009.02115.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.